Latest News

Study provides new analysis of isotretinoin and risk for adverse neuropsychiatric outcomes

Publish date: May 5, 2022

 

FROM THE BRITISH JOURNAL OF DERMATOLOGY

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Dermatologists take to TikTok to share their own ‘hacks’
MDedge Dermatology
iPLEDGE rollout described as a failure, chaotic, and a disaster
MDedge Dermatology
iPLEDGE rollout: As frustration mounts, FDA agrees to help solve issues
MDedge Dermatology
FDA updates status of iPLEDGE access problems
MDedge Dermatology
More than a month after launch, iPLEDGE glitches persist
MDedge Dermatology
Questions about optimal dosing of isotretinoin persist, expert says
MDedge Dermatology
Oral Isotretinoin for Acne in the US Military: How Accelerated Courses and Teledermatology Can Minimize the Duty-Limiting Impacts of Treatment
MDedge Dermatology
Spironolactone not linked to increased cancer risk in systematic review and meta-analysis
MDedge Dermatology
Removal of Isotretinoin Gender-Based Guidelines: Inclusivity Takes Precedence
MDedge Dermatology
Cupping in dermatology
MDedge Dermatology